Results 11 to 20 of about 191 (157)

Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer. [PDF]

BJS Open, 2020
Deconditioning during neoadjuvant chemotherapy is a possible parameter for predicting operative outcomes. This retrospective cohort study aimed to assess body composition changes in patients with gastro‐oesophageal cancer during neoadjuvant therapy and investigate their association with postoperative complications. Skeletal muscle index values decrease
den Boer RB, Jones KI, Ash S, van Boxel GI, Gillies RS, O'Donnell T, Ruurda JP, Sgromo B, Silva MA, Maynard ND.   +9 more
europepmc   +2 more sources

Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma. [PDF]

BJS Open, 2020
The neutrophil to lymphocyte ratio, dichotomized at 2·25, was strongly associated with Mandard tumour regression grade in patients who had neoadjuvant chemotherapy for oesophageal adenocarcinoma. The systemic inflammatory response may offer a novel therapeutic target for patients at risk of poor response.
Powell AGMT, Chin C, Coxon AH, Chalishazar A, Christian A, Roberts SA, Lewis WG.   +6 more
europepmc   +2 more sources

Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases. [PDF]

BJS Open, 2019
This study aimed to estimate the effect of neoadjuvant FOLFOX in patients undergoing upfront resectable colorectal liver metastases. After adjustment, no significant impact of FOLFOX was detected, suggesting that upfront surgery may be acceptable in patients with limited disease.
Allard MA, Nishioka Y, Beghdadi N, Imai K, Gelli M, Yamashita S, Kitano Y, Kokudo T, Yamashita YI, Sa Cunha A, Vibert E, Elias D, Cherqui D, Goere D, Adam R, Baba H, Hasegawa K.   +16 more
europepmc   +2 more sources

Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. [PDF]

BJS Open, 2019
A positive circumferential resection margin (CRM) has been shown to be an adverse prognostic indicator after oesophagectomy for adenocarcinoma. Clinical tumour status, tumour volume, poor differentiation, lack of response following chemotherapy and radiological assessment of invasion can be used to predict CRM positivity in oesophageal adenocarcinoma ...
Knight WRC, Yip C, Wulaningsih W, Jacques A, Griffin N, Zylstra J, Van Hemelrijck M, Maisey N, Gaya A, Baker CR, Kelly M, Gossage JA, Lagergren J, Landau D, Goh V, Davies AR, Guy's and St Thomas' Oesophago‐Gastric Research Group, Ngan S, Qureshi A, Deere H, Green M, Chang F, Mahadeva U, Gill-Barman B, George S, Dunn J, Zeki S, Meenan J, Hynes O, Tham G, Iezzi C.   +30 more
europepmc   +2 more sources

Quimioterapia neoadyuvante en cáncer de mama, localmente avanzado

Correo Científico Médico, 2013
Introducción: el cáncer de mama es actualmente el tumor maligno más frecuente en la mujer y la quimioterapia constituye una de las principales armas terapéuticas en este padecimiento. Objetivo: caracterizar el comportamiento de los enfermos con cáncer
Alexander Portelles Cruz, Yamilka Rodríguez Alberteris, Pedro Antonio Fernández Sarabia, Nitza Julia Sanz Pupo, Jackeline Oller Pousada   +4 more
doaj   +1 more source

Tumor response to neoadjuvant chemotherapy in molecular breast cancer subtypes in Medellin, Colombia. Retrospective cohort study [PDF]

Rev Colomb Obstet Ginecol, 2023
Objetivos: describir la frecuencia de la respuesta clínica y patológica, entre los diferentes subtipos moleculares de cáncer de mama, en pacientes que previamente recibieron quimioterapia neoadyuvante.
Restrepo-Mejía M, Guarín-García AM, Bonilla-Sepúlveda ÓA, Rincón-Medina M, Barrera-Arenas LM.   +4 more
europepmc   +2 more sources

Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia [PDF]

Biomedica, 2023
Introduction. Breast cancer is the most common type of cancer and the leading cause of death by cancer in women in Colombia. Approximately 15 to 20% of breast cancers overexpress HER2. Objective.
Rodríguez M, González DM, El-Sharkawy F, Castaño M, Madrid J.   +4 more
europepmc   +2 more sources

¿La quimioterapia neoadyuvante proporciona algún beneficio para la desescalada quirúrgica en el cáncer de mama HER2 (−) luminal B?

Cirugía y Cirujanos, 2023
Antecedentes. El uso de quimioterapia neoadyuvante (QTN) en cáncer de mama (CB) menos agresivo es controversial. Objetivo: Investigar el efecto de la quimioterapia neoadyuvante en el cáncer de mama HER2 negativo luminal B. Método.
Aysegul Aktas, Meryem Gunay-Gurleyik, Fugen Aker, Yasar Kaan-Akgok, Elif Atag   +4 more
doaj   +1 more source

Eficacia de biopsia de ganglio centinela en cáncer de mama posterior a quimioterapia neoadyuvante como predictor de estadificación axilar.

Oncología, 2023
Introducción: La biopsia selectiva del ganglio centinela (BSGC) en cáncer de mama es el método estándar para estadificación axilar en pacientes con axila clínicamente negativa.
Carlos Humberto Malatay González, Cinthya Abigail Apolo Carrión, Felix Josué Carofilis Gallo, Maria Elena Zamora Villavicencio   +3 more
doaj   +1 more source

Últimos avances en el tratamiento neoadyuvante de cáncer de vejiga

Acta Médica Peruana, 2022
La quimioterapia neoadyuvante basada en cisplatino ha demostrado un claro beneficio en cáncer de vejiga músculo invasivo (MIBC) EC II o IIIA, logrando un impacto en la sobrevida libre de progresión y sobrevida global. Esta revisión actualizada se centra
Patricia Rioja, Guillermo Valencia, Zaida Morante, Roberto Paz, Heberth Vallejos, Hugo Fuentes, Silvia Neciosup   +6 more
doaj   +1 more source